COVID-19 Acute Respiratory Distress SyndromePERCECOVACNCT04896957
Perceptions and Representations of Vaccination Against COVID-19
An observational study of COVID-19 Acute Respiratory Distress Syndrome, run by Centre Hospitalier Intercommunal Creteil at 1 site in France.
Trial summary
SARS COV2, the virus that causes COVID-19, was first described in Wuhan, China. For this pathology, which causes severe respiratory infections, preventing the transmission of the virus has become fundamental, that is why vaccines have been developed. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COVID-19 Acute Respiratory Distress Syndrome
- What is being tested?
- Interview
- Type of treatment
- Vaccines, Lifestyle or therapy programme
- How many people
- 14 participants
- Where
- 1 siteFrance
- Study dates
- 1 Sep 2021to 1 Sep 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with or without comorbidities consulting the Villeneuve Saint Georges Hospital for COVID-19 vaccination or for a scheduled consultation
Who may be able to join
- Over 18 years of age
- Patient with a scheduled appointment in consultation or at the vaccination centre
- Not opposed to participation in the protocol
Who cannot join
- Patient under guardianship or curatorship
- Patient unable to give free and informed consent
- Patient under court protection
- Patient without the cognitive capacity to ensure an interview
Trial locations and contacts
1 site in 1 country.
About this study
SARS COV2, the virus that causes COVID-19, was first described in Wuhan, China. For this pathology, which causes severe respiratory infections, preventing the transmission of the virus has become fundamental, that is why vaccines have been developed. In France, this vaccination campaign took place in a context where the lack of confidence in vaccination is high:
According to a November 2020 IFOP poll, only 41% of French respondents were willing to be vaccinated against COVID-19.
To our knowledge, there are still few qualitative studies on vaccination on the current issue of vaccination against COVID-19.
- Being tested
- Interview
- Keywords
- vaccination perception
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
InterviewBehavioural
Face to face semi-directed interviews about perceptions, representations and experiences of Covid-19 vaccination, including six opened-questions
What is being measured
The primary outcome is the main question the study is designed to answer.
Perceptions, representations and experiences of Covid-19 vaccination
Interview based on 6 opened questions
Measured: 1 hour
Secondary outcomes (1)
Key elements to improve the medical discourse on vaccination
Interview based on 6 opened questions
Measured: 1 hour
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 May 2021
- Study start1 Sep 2021
- Primary completion1 Sep 2022
- Study completion1 Sep 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19 Acute Respiratory Distress SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 14 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Intercommunal Creteil
- Sponsor type
- University, hospital or other
- Collaborators
- Centre Hospitalier Intercommunal Villeneuve Saint Georges
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04896957
- Sponsor's protocol ID
- PERCECOVAC
- Acronym
- PERCECOVAC
- Status last verified
- Dec 2022
- First submitted
- 20 May 2021
- Last updated
- 2 Dec 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Dec 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Perceptions and Representations of Vaccination Against COVID-19
- ClinicalTrials.gov ID
- NCT04896957
- Acronym / sponsor ID
- PERCECOVAC / PERCECOVAC
- Keywords
- vaccination perception
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 14 participants (actual)
- Lead sponsor
- Centre Hospitalier Intercommunal CreteilUniversity, hospital or other
- Collaborators
- Centre Hospitalier Intercommunal Villeneuve Saint Georges
- Study start
- 1 Sep 2021 (actual)
- Primary completion
- 1 Sep 2022 (actual)
- Study completion
- 1 Sep 2022 (actual)
- First posted
- 21 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
SARS COV2, the virus that causes COVID-19, was first described in Wuhan, China. For this pathology, which causes severe respiratory infections, preventing the transmission of the virus has become fundamental, that is why vaccines have been developed. In France, this vaccination campaign took place in a context where the lack of confidence in vaccination is high:
According to a November 2020 IFOP poll, only 41% of French respondents were willing to be vaccinated against COVID-19.
To our knowledge, there are still few qualitative studies on vaccination on the current issue of vaccination against COVID-19.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with or without comorbidities consulting the Villeneuve Saint Georges Hospital for COVID-19 vaccination or for a scheduled consultation
Key inclusion criteria (3 listed)
- Over 18 years of age
- Patient with a scheduled appointment in consultation or at the vaccination centre
- Not opposed to participation in the protocol
Key exclusion criteria (4 listed)
- Patient under guardianship or curatorship
- Patient unable to give free and informed consent
- Patient under court protection
- Patient without the cognitive capacity to ensure an interview
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| InterviewFace to face semi-directed interviews about perceptions, representations and experiences of Covid-19 vaccination, including six opened-questions | Behavioural | – |
Primary outcome
Perceptions, representations and experiences of Covid-19 vaccination
Time frame: 1 hour
Interview based on 6 opened questions
1 secondary outcome
Key elements to improve the medical discourse on vaccination
Time frame: 1 hour
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Dec 2022.
- Individual participant dataSharing planned: No
Related trials for COVID-19 Acute Respiratory Distress Syndrome
Not yet recruitingPhase 1
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
ARDS, Covid19
RecruitingPhase 3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Viral Lung Infection and Acute Respiratory Failure
Active, not recruitingPhase 1/2
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome
Active, not recruitingPhase 2
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
Acute Respiratory Distress Syndrome, Viral or Bacterial Infections
RecruitingPhase 1/2
Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2)
Systemic Inflammatory Response Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19 Acute Respiratory Distress Syndrome, run by Centre Hospitalier Intercommunal Creteil at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Perceptions, representations and experiences of Covid-19 vaccination (time frame: 1 hour). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Dec 2022.